Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

2.

An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).

Gray A, Clarke P, Raikou M, Adler A, Stevens R, Neil A, Cull C, Stratton I, Holman R; UKPDS Group.

Diabet Med. 2001 Jun;18(6):438-44.

PMID:
11472461
[PubMed - indexed for MEDLINE]
3.

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

[No authors listed]

BMJ. 1998 Sep 12;317(7160):703-13. Erratum in: BMJ 1999 Jan 2;318(7175):29.

PMID:
9732337
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).

Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR; UKPDS 72 United Kingdom Prospective Diabetes Study.

Diabetologia. 2005 May;48(5):868-77. Epub 2005 Apr 15.

PMID:
15834550
[PubMed - indexed for MEDLINE]
6.

Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.

Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group.

Arch Ophthalmol. 2004 Nov;122(11):1631-40.

PMID:
15534123
[PubMed - indexed for MEDLINE]
7.

Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.

[No authors listed]

Diabetologia. 1996 Dec;39(12):1554-61. Erratum in: Diabetologia 1997 Mar;40(3):366.

PMID:
8960842
[PubMed - indexed for MEDLINE]
8.

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

CDC Diabetes Cost-effectiveness Group.

JAMA. 2002 May 15;287(19):2542-51.

PMID:
12020335
[PubMed - indexed for MEDLINE]
9.

Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.

Jönsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlöf B; LIFE Study Group.

J Hypertens. 2005 Jul;23(7):1425-31.

PMID:
15942467
[PubMed - indexed for MEDLINE]
11.

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B; ASCOT investigators.

Pharmacoeconomics. 2009;27(3):221-30. doi: 10.2165/00019053-200927030-00005.

PMID:
19354342
[PubMed - indexed for MEDLINE]
12.
13.

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R.

BMJ. 2000 May 20;320(7246):1373-8.

PMID:
10818026
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.

Curr Med Res Opin. 2007 Mar;23(3):609-22.

PMID:
17355742
[PubMed - indexed for MEDLINE]
15.

[Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].

Keiding H, Hildebrandt P, Burke T, Carides GW.

Ugeskr Laeger. 2006 Oct 16;168(42):3623-6. Danish.

PMID:
17069726
[PubMed - indexed for MEDLINE]
16.

Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B; ASCOT trial investigators.

Heart. 2008 Feb;94(2):e4. Epub 2007 Oct 4.

PMID:
17916665
[PubMed - indexed for MEDLINE]
17.

A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy.

Anis AH, Sun H, Singh S, Woolcott J, Nosyk B, Brisson M.

Pharmacoeconomics. 2006;24(4):387-400.

PMID:
16605284
[PubMed - indexed for MEDLINE]
18.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
19.

Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.

Tunis SL.

Appl Health Econ Health Policy. 2011 Nov 1;9(6):351-65. doi: 10.2165/11594270-000000000-00000.

PMID:
21892840
[PubMed - indexed for MEDLINE]
20.

Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.

Dong FB, Sorensen SW, Manninen DL, Thompson TJ, Narayan V, Orians CE, Gregg EW, Eastman RC, Dasbach EJ, Herman WH, Newman JM, Narva AS, Ballard DJ, Engelgau MM.

Pharmacoeconomics. 2004;22(15):1015-27.

PMID:
15449965
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk